Breaking Finance News

Gerresheimer (ETR:GXI) target price raised to 80.00EUR, issued a report today by Hauck & Aufhäuser Privatbankiers KGaA

Gerresheimer (ETR:GXI) had its price target upped to 80.00EUR by Hauck & Aufhäuser Privatbankiers KGaA in a report released 10/08/2016. The new stock price target implies a possible upside of 0.09% based on the company's most recent close.

On Friday October 07, 2016, Hauck & Aufhäuser Privatbankiers KGaA released a statement for Gerresheimer (ETR:GXI) bumped up the target price from 0.00EUR to 80.00EUR that suggested an upside of 0.08%.

Boasting a price of 73.37EUR, Gerresheimer (ETR:GXI) traded 0.00% even on the day. With the last stock price close up 0.00% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Gerresheimer has recorded a 50-day average of 0.00EUR and a two hundred day average of 0.00EUR. Volume of trade held steady, with 0 shares of GXI changing hands on par with the typical 0

Performance Chart

Gerresheimer (ETR:GXI)

With a total market value of 0 EUR, Gerresheimer has with a one year low of 0.00EUR and a one year high of 0.00EUR .

Brief Synopsis About Gerresheimer (ETR:GXI)

Gerresheimer AG is a Germany-based company that operates in the pharmaceuticals and health care industry. It is structured in three business segments: Plastic and Devices, Primary Packaging Glass and Life Science Research. The Company produces pharmaceutical packaging products, as well as drug-delivery systems made out of glass and plastics or a combination of both. Its product portfolio includes insulin pens, inhalers, pre-fillable syringes, vials, ampoules, bottles and containers for liquid and solid pharmaceuticals with closure and safety systems, plus cosmetic packaging products. The Company operates approximately 40 production facilities in Europe, North America, South America and Asia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *